A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy

Aims The recent American College of Cardiology and American Heart Association Guidelines on hypertrophic cardiomyopathy (HCM) have confirmed surgical myectomy as the gold standard for non-pharmacological treatment of obstructive HCM. However, during the last 15 years, an extensive use of alcohol septal ablation has led to the virtual extinction of myectomy programmes in several European countries. Therefore, many HCM candidates for myectomy in Europe cannot be offered the option of this procedure. The purpose of our study is to report the difficulties and results in developing a myectomy programme for HCM in a centre without previous experience with this procedure. Methods and results The clinical course is reported of 124 consecutive patients with obstructive HCM and heart failure symptoms who underwent myectomy at a single European centre between 1996 and 2010. The median follow-up was 20.3 months (inter-quartile range: 3.9–40.6 months). No patients were lost to follow-up. A cumulative incidence of HCM-related death after myectomy was 0.8, 3.3, and 11.2% at 1, 5, and 10 years, respectively, including one operative death (procedural mortality 0.8%). The left ventricular (LV) outflow gradient decreased from 95 ± 36 mmHg before surgery to 12 ± 6 mmHg at most recent evaluation (P < 0.001), with none of the patients having a significant residual LV outflow gradient. Of the 97 patients in New York Heart Association functional class III–IV before surgery, 93 (96%) were in class I–II at most recent evaluation (P < 0.001). Conclusion Our results show that the development of a myectomy programme at a centre without previous experience with this procedure is feasible and can lead to highly favourable clinical results.

[1]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[2]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[3]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[4]  S. Jedrzkiewicz,et al.  The mitral valve in hypertrophic cardiomyopathy: it's a long story. , 2011, Circulation.

[5]  M. Yacoub,et al.  Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. , 2011, European heart journal.

[6]  U. Sigwart,et al.  Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. , 2011, European heart journal.

[7]  W. Manning,et al.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.

[8]  P. Serruys,et al.  Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy: A Word of Caution , 2010, Circulation. Heart failure.

[9]  I. Palacios,et al.  Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[10]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[11]  M. Gold,et al.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[12]  S. Ommen,et al.  Myths about surgical myectomy: rumors of its death have been greatly exaggerated. , 2008, The American journal of cardiology.

[13]  B. Gersh,et al.  Surgery Insight: septal myectomy for obstructive hypertrophic cardiomyopathy—the Mayo Clinic experience , 2007, Nature Clinical Practice Cardiovascular Medicine.

[14]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[15]  B. Maron.  Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy , 2007 .

[16]  B. Maron.  Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. , 2007, Circulation.

[17]  P. Oettgen,et al.  Controversies in Cardiovascular Medicine , 2006 .

[18]  M. Gold,et al.  Sustained Ventricular Tachycardia Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[19]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[20]  M. Yacoub.  Surgical Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: The Pendulum Swings , 2005, Circulation.

[21]  P. Serruys,et al.  Percutaneous Versus Surgical Treatment for Patients With Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets , 2005, Circulation.

[22]  U. Sigwart,et al.  Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. , 2005, Circulation.

[23]  M. Götte,et al.  Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy , 2005, Circulation.

[24]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[25]  C. Autore,et al.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.

[26]  J. Dearani,et al.  Septal myectomy for obstructive hypertrophic cardiomyopathy , 2004 .

[27]  T. Ports,et al.  Ventricular tachycardia complicating alcohol septal ablation. , 2004, The New England journal of medicine.

[28]  B. Maron,et al.  Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. , 2004, The Journal of thoracic and cardiovascular surgery.

[29]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[30]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[31]  F. T. ten Cate,et al.  Sustained Improvement After Combined Anterior Mitral Leaflet Extension and Myectomy in Hypertrophic Obstructive Cardiomyopathy , 2003, Circulation.

[32]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[33]  E. D. Wigle,et al.  Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy , 2003 .

[34]  A. Tajik,et al.  Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. , 2002, The American journal of cardiology.

[35]  M. S. Hamid,et al.  Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. , 2002, European heart journal.

[36]  H. Kuhn,et al.  Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions , 2002, Circulation.

[37]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[38]  M. Henein,et al.  Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[39]  K. Borisov,et al.  Management of Symptomatic Hypertrophic Obstructive Cardiomyopathy - Long-Term Results after Surgical Therapy , 1999, The Thoracic and cardiovascular surgeon.

[40]  B. Maron,et al.  Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[41]  B. Maron,et al.  Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. , 1998, Circulation.

[42]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[43]  F. Flachskampf,et al.  Quantitative assessment of the operative results after extended myectomy and surgical reconstruction of the subvalvular mitral apparatus in hypertrophic obstructive cardiomyopathy using dynamic three-dimensional transesophageal echocardiography. , 1998, Journal of the American College of Cardiology.

[44]  F. Flachskampf,et al.  Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. , 1995, Circulation.

[45]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[46]  E. Godehardt,et al.  Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years. , 1993, The Journal of thoracic and cardiovascular surgery.

[47]  B. Maron,et al.  Initial Results of Combined Anterior Mitral Leaflet Plication and Ventricular Septal Myotomy‐Myectomy for Relief of Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy , 1992, Circulation.

[48]  W. Williams,et al.  Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. , 1992, Journal of the American College of Cardiology.

[49]  W. Roberts,et al.  Anomalous Insertion of Papillary Muscle Directly Into Anterior Mitral Leaflet in Hypertrophic Cardiomyopathy: Significance in Producing Left Ventricular Outflow Obstruction , 1991, Circulation.